CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025

Core Points - National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. for the period between March 17, 2022, and September 22, 2022 [1][3] - The class action lawsuit alleges that Spectrum made false or misleading statements regarding its Pinnacle Study, which involved the drug poziotinib for lung cancer treatment [3] - Spectrum shares were delisted following the merger with Assertio Holdings, Inc. [3] Company Information - Spectrum Pharmaceuticals is a biopharmaceutical company focused on oncology treatments [2] - Investors who acquired Spectrum securities during the specified class period have until September 24, 2025, to seek appointment as lead plaintiff representatives [2] Legal Context - Berger Montague has a long history in securities class action litigation, representing individual and institutional investors since 1970 [5]